Acclaro Medical, a Smithfield, RI-based medical technology company focused on developing solutions for patient care and medical practices, raised $23M in Series B funding.
The round was led by Accelmed Partners with participation from existing investor 3E Bioventures Capital.
The company intends to use the funds to accelerate the growth of its flagship products, UltraClear and AuraLux, and expedite global market expansion while advancing development of new products in its pipeline.
Led by CEO Helen Fang, Acclaro Medical develops innovates and brings to market solutions to address unmet medical, aesthetic and surgical practice needs. Its flagship product, UltraClear, is a cold, ablative fiber laser platform, a painless anti-aging solution not requiring topical numbing for most treatments. Empowered by the 3DMIRACL and 3DIntelliPulse technologies, the company offers a full range of skin rejuvenation outcomes from painless and zero-downtime anti-aging lunchtime treatments to most advanced collagen remodeling.
FinSMEs
29/05/2025